| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +5.9K | +19.52% | $0.00 | 36.1K | Feb 15, 2024 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +1.57K | +4.35% | $0.00 | 37.7K | Feb 15, 2024 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +1.48K | +3.92% | $0.00 | 39.2K | Feb 15, 2024 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +2.14K | +5.46% | $0.00 | 41.3K | Feb 15, 2024 | Direct | F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to buy) | Award | $0 | +13.9K | $0.00 | 13.9K | Feb 15, 2024 | Common Stock | 13.9K | $175.28 | Direct | F5, F6 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| F5 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027. |
| F6 | Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 but the correct value of $175.28 is reflected in this amendment. |
Due to an administrative error, this amendment corrects the award amounts in Table I, Column 5, and the exercise price in Table II, Column 2, for the common stock awards and option grant included in the Form 4 filed on February 20, 2024. The correct amounts are now reflected in this amendment.